Pantethine: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Pantethine is chemical that occurs naturally in the body. It's related to vitamin B5 (pantothenic acid).

Pantethine might increase concentrations of some chemicals that lower blood cholesterol and triglycerides in the body.

People use pantethine for lowering levels of cholesterol and triglycerides. It is also used for athletic performance and other purposes, but there is no good scientific evidence to support these uses.

In Japan and China, pantethine is available as a prescription drug for hyperlipidemia. Don't confuse pantethine with pantothenic acid. These are not the same.

Uses & Effectiveness

Possibly Effective for

High levels of lipoproteins in the blood (hyperlipoproteinemia). Taking pantethine by mouth might modestly lower triglycerides, total cholesterol, and low-density lipoprotein (LDL or "bad") cholesterol, and raise high-density lipoprotein (HDL or "good") cholesterol, in people with this inherited condition. But it doesn't seem to work as well as conventional drugs.

There is interest in using pantethine for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Side Effects

When taken by mouth: Pantethine is possibly safe when used in doses of up to 1000 mg daily for up to 48 weeks. It might cause nausea, diarrhea, and stomach discomfort in some people.

Special Precautions and Warnings

When taken by mouth: Pantethine is possibly safe when used in doses of up to 1000 mg daily for up to 48 weeks. It might cause nausea, diarrhea, and stomach discomfort in some people.

Pregnancy and breast-feeding: There isn't enough reliable information to know if pantethine is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Bleeding disorders: Pantethine might slow blood clotting. This might increase the risk of severe bleeding in patients with bleeding disorders. If you have a bleeding disorder, talk to your healthcare provider before starting pantethine.

Surgery: Pantethine might slow blood clotting. This might increase the risk of bleeding during and after surgery. Stop using pantethine at least 2 weeks before a scheduled surgery.

Interactions

Moderate Interaction

Be cautious with this combination

Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with Pantethine
Pantethine might slow blood clotting. Taking pantethine along with medications that also slow blood clotting might increase the risk of bruising and bleeding.

Dosing

Pantethine has most often been used by adults in doses of 600-900 mg by mouth daily for 2-3 months. Speak with a healthcare provider to find out what dose might be best for a specific condition.

View References

REFERENCES:

Murai A, Miyahara T, Tanaka T, et al. The effects of pantethine on lipid and lipoprotein abnormalities in survivors of cerebral infarction. Artery 1985;12:234-43.

Maggi GC, Donati C, Criscuoli G. Pantethine: a physiological lipomodulating agent in the treatment of hyperlipidemias. Curr Ther Res 1982;32:380-6.

Da Col PG, Cattin L, Fonda M, et al. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol. Curr Ther Res 1984;36:314-22.

Rubba P, Postaiglione B, De Simone F, et al. Comparative evaluation of the lipid-lowering effects of fenofibrate and pantethine in type II hyperlipoproteinemia. Curr Ther Res 1985;38:719-27.

Angelica M, Pinto G, Ciaccheri C, et al. Improvement in serum lipid profile in hyperlipoproteinemia patients after treatment with pantethine: a cross-over double-blind trial versus placebo. Curr Ther Res 1983;33:1091-7.

Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis 1984;50:73-83.

Prisco D, Rogasi PG, Matucci M, et al. Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyperlipoproteinemia. Angiology 1987;38:241-7.

McCarty MF. Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Med Hypotheses 2001;56:314-7.

Cighetti G, Del Puppo M, Paroni R, Galli Kienle M. Modulation of HMG-CoA reductase activity by pantetheine/pantethine. Biochim Biophys Acta 1988;963:389-93.

Carrara P, Matturri L, Galbussera M, et al. Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits. Atherosclerosis 1984;53:255-64.

Congdon NT, West ST, Duncan DT, et al. The effect of pantethine and ultraviolet-B radiation on the development of lenticular opacity in the emory mouse. Curr Eye Res 2000;20:17-24.

Hiraoka T, Clark JI, LI XY, Thurston GM. Effect of selected anti-cataract agents on opacification in the selenite cataract model. Exp Eye Res 1996;62:11-9.

Clark JI, Livesey JC, Steele JE. Delay or inhibition of rat lens opacification using pantethine and WR-77913. Exp Eye Res 1996;62:75-84.

Kelly GS. Nutritional and botanical interventions to assist with the adaptation to stress. Altern Med Rev 1999;4:249-65..

Butler JD, Zatz M. Pantethine depletes cystinotic fibroblasts of cystine. J Pediatr 1983;102:796-8.

Anonymous. Pantethine. Altern Med Rev 1998;3:379-81.

Coronel F, Tornero F, Torrente J, et al. Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance. Am J Nephrol 1991;11:32-6..

Wittwer CT, Graves CP, Peterson MA, et al. Pantethine lipomodulation: evidence for cysteamine mediation in vitro and in vivo. Atherosclerosis 1987;68:41-9..

Bon GB, Cazzolato G, Zago S, et al. Effects of pantethine on in-vitro peroxidation of low density lipoproteins. Atherosclerosis 1985;57:99-106..

Ranganathan S, Jackson RL, Harmony JA. Effect of pantethine on the biosynthesis of cholesterol in human skin fibroblasts. Atherosclerosis 1982;44:261-73..

Agrati AM, Ambrosi G, Ferraro G, Palmieri. Gemfibrozil efficacy vs pantethine in dyslipoproteinemic patients: a controlled study. Curr Ther Res 1989;45:650-63.

Donati C, Barbi G, Cairo G, et al. Pantethine improves the lipid abnormalities of chronic hemodialysis patients: results of a multicenter clinical trial. Clin Nephrol 1986;25:70-4..

Arsenio L, Bodria P, Magnati G, et al. Effectiveness of long-term treatment with pantethine in patients with dyslipidemia. Clin Ther 1986;8:537-45..

Webster MJ. Physiological and performance responses to supplementation with thiamin and pantothenic acid derivatives. Eur J Appl Physiol Occup Physiol 1998;77:486-91.

Osono, Y., Hirose, N., Nakajima, K., and Hata, Y. The effects of pantethine on fatty liver and fat distribution. J.Atheroscler.Thromb. 2000;7(1):55-58.

Tonutti, L., Taboga, C., and Noacco, C. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia]. Minerva Med. 1991;82(10):657-663.

Penet, M. F., Abou-Hamdan, M., Coltel, N., Cornille, E., Grau, G. E., de, Reggi M., and Gharib, B. Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc.Natl.Acad.Sci.U.S.A 1-29-2008;105(4):1321-1326.

Ishihara, M., Iihara, H., Okayasu, S., Yasuda, K., Matsuura, K., Suzui, M., and Itoh, Y. Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients. Support.Care Cancer 2010;18(12):1531-1538.

Rumberger, J. A., Napolitano, J., Azumano, I., Kamiya, T., and Evans, M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr.Res. 2011;31(8):608-615.

Binaghi, P., Cellina, G., Lo, Cicero G., Bruschi, F., Porcaro, E., and Penotti, M. [Evaluation of the cholesterol-lowering effectiveness of pantethine in women in perimenopausal age]. Minerva Med. 1990;81(6):475-479.

Donati, C., Bertieri, R. S., and Barbi, G. [Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients]. Clin.Ter. 3-31-1989;128(6):411-422.

Lu, Z. L. [A double-blind clinical trial--the effects of pantethine on serum lipids in patients with hyperlipidemia]. Zhonghua Xin.Xue.Guan.Bing.Za Zhi. 1989;17(4):221-223.

Eto, M., Watanabe, K., Chonan, N., and Ishii, K. Lowering effect of pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus. Artery 1987;15(1):1-12.

Arsenio, L., Bodria, P., Bossi, S., Lateana, M., and Strata, A. [Clinical use of pantethine by parenteral route in the treatment of hyperlipidemia]. Acta Biomed.Ateneo.Parmense. 1987;58(5-6):143-152.

Bertolini, S., Donati, C., Elicio, N., Daga, A., Cuzzolaro, S., Marcenaro, A., Saturnino, M., and Balestreri, R. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int.J.Clin.Pharmacol.Ther.Toxicol. 1986;24(11):630-637.

Borets, V. M., Lis, M. A., Pyrochkin, V. M., Kishkovich, V. P., and Butkevich, N. D. [Therapeutic efficacy of pantothenic acid preparations in ischemic heart disease patients]. Vopr.Pitan. 1987;(2):15-17.

Bergesio, F., Ciuti, R., Innocenti, D., Galli, G. A., and Frizzi, V. [Use of pantethine in dyslipidemia of chronic uremic patients under dialysis treatment]. G.Clin.Med. 1985;66(11-12):433-440.

Postiglione, A., Rubba, P., Cicerano, U., Chierchia, I., and Mancini, M. Pantethine versus fenofibrate in the treatment of type II hyperlipoproteinemia. Monogr Atheroscler. 1985;13:145-148.

Vignola, D., Fanini, A., and Biffignandi, P. [Effects of D(+)-bis-(N-pantothenyl-amidoethyl)-disulphur on the blood lipid profile and apoproteins A and B levels]. Clin.Ter. 6-30-1985;113(6):479-483.

Wittwer, C. T., Gahl, W. A., Butler, J. D., Zatz, M., and Thoene, J. G. Metabolism of pantethine in cystinosis. J.Clin.Invest 1985;76(4):1665-1672.

Seghieri, G., Maffucci, G., Toscano, G., Santoni, F., Tuci, S., and De Giorgio, L. A. [Effect of pantethine therapy in chronic uremic patients undergoing hemodialysis with type IV hyperlipoproteinemia]. G.Clin.Med. 1985;66(5-6):187-192.

Gensini, G. F., Prisco, D., Rogasi, P. G., Matucci, M., and Neri Serneri, G. G. Changes in fatty acid composition of the single platelet phospholipids induced by pantethine treatment. Int.J.Clin.Pharmacol.Res. 1985;5(5):309-318.

Arsenio, L., Caronna, S., Lateana, M., Magnati, G., Strata, A., and Zammarchi, G. [Hyperlipidemia, diabetes and atherosclerosis: efficacy of treatment with pantethine]. Acta Biomed.Ateneo.Parmense. 1984;55(1):25-42.

Hiramatsu, K., Nozaki, H., and Arimori, S. Influence of pantethine on platelet volume, microviscosity, lipid composition and functions in diabetes mellitus with hyperlipidemia. Tokai J.Exp.Clin.Med. 1981;6(1):49-57.

Nomura, H., Kimura, Y., Okamoto, O., and Shiraishi, G. Effects of antihyperlipidemic drugs and diet plus exercise therapy in the treatment of patients with moderate hypercholesterolemia. Clin.Ther. 1996;18(3):477-482.

McRae MP. Treatment of hyperlipoproteinemia with pantethine: A review and analysis of efficacy and tolerability. Nutrition Res 2005;25:319-333.

Da Col, P. G., Cattin, L., Fonda, M., and et al. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol. Current Therapeutic Research 1984;38:719-727.

Maggi, G. C., Donati, C., and Criscuoli, G. Pantethine: physiological lipomodulating agent, in the treatment of hyperlipidemias. Current Therapeutic Research 1982;32(Sep):380-386.

Agrati, A. M., Ambrosi, G., Ferraro, G., and Palmieri, G. Gemfibrozil efficacy vs. pantethine in dyslipoproteinemic patients: controlled study. Current Therapeutic Research 1989;45(Apr):650-663.

Coronel, F., Tornero, F., Torrente, J., Naranjo, P., De Oleo, P., Macia, M., and Barrientos, A. Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance. Am.J.Nephrol. 1991;11(1):32-36.

Rubba, P., Postiglione, A., De Simone, B., Lamenza, F., and Mancini, M. Comparative evaluation of the lipid-lowering effects of fenofibrate and pantethine in type II hyperlipoproteinemia. Current Therapeutic Research 1985;38(May):719-727.

Cattin, L., Da Col, P. G., Fonda, M., Mameli, M. G., and Fergulio, G. A. Treatment of hypercholesterolemia with pantethine and fenofibrate; open randomized study on 43 subjects. Current Therapeutic Research 1985;38(Sep):386-395.

Capurso A, Resta F, Ciancia D, Lavezzari M, Mogavero AM, Taverniti R, Di TM, Siciliani G, and Palmisano S. Effect of acipimox and pantethine on serum lipids and apoproteins in patients with type II hyperlipoproteinemia. Current Therapeutic Research 1987;42(6):1216-1222.

Maioli, M., Pacifico, A., and Cherchi, G. M. Effect of pantethine on the subfractions of HDL in dislipidemic patients. Current Therapeutic Research 1984;35(Feb):307-311.

Angelico, M., Pinto, G., Ciaccheri, C., Alvaro, D., and De Santis, A. Improvement in serum lipid profile in hyperlipoproteinemic patients after treatment with pantethine: crossover, double blind trial versus placebo. Current Therapeutic Research 1983;33(June Sec 2):1091-1097.

Avogaro, P., Bon, G. B., and Fusello, M. Effects of pantethine on lipids, lipoproteins and apolipoproteins in man. Current Therapeutic Research 1983;33(Mar):488-493.

Angelica M, Pinto G Ciaccheri C et al. Improvement in serum lipid profile in hyperlipoproteinemia patients after treatment with pantethine: a cross-over double-blind trial versus placebo. Curr Ther Res 1983;33:1091-1097.

Bellani, F., Colnago, R., Meregalli, M., Scarpazza, P., and Donati, C. Treatment of hyperlipidemias complicated by cardiovascular diseases in the elderly: results of an open short term study with pantethine. Current Therapeutic Research 1986;40(Nov):912-916.

Binaghi P, Cellina G LoCicero G Bruschi F Porcaro E Penotti M. Evaluation of the hypocholesterolemic activity of pantethine in perimenopausal women. Minerva Med 1990;81:475-479.

Bellani F, Colnago R Meregalli M Scarpazza P Sesia O Donati C. Treatment of hyperlipidemias complicated by cardiovascular diseases in the elderly: results of an open short-term study with pantethine. Curr Ther Res 1986;40:912-916.

Giannini S, Forti N DiRienzo F Campanari J Ziliotto E. Efeitos da pantetina sobrelipides sangineos. ArqBras Cardiol 1986;46:283-289.

Cattin L, DaCol P Fonda M Mameli M Pilotto L Vanuzzo D et al. Treatment of hypercholesterolemia with pantethine and fenofibrate: an open randomized study on 43 subjects. Curr Ther Res 1985;38:386-395.

Bosello O, Cominacini L Garrbin U Ferrari F Zocca I Davoli A et al. Changes in the very low density lipoprotein distribution of apolipoproteins C-III2, C-III1, C-III0, C-II and apolipoprotein E after pantethine administration. Acta Ther 1984;10:421-430.

Da Col P, Cattin L Fonda M Mameli M Feruglio F. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol. Curr Ther Res 1984;36:214-221.

Miccoli R, Marchetti P Sampietro T Benzi L Tognarelli M Navalesi R. Effects of pantethine on lipids and apolipoproteins in hypercholesterolemic diabetic and non-diabetic patients. Curr Ther Res 1984;36:545-549.

Maioli M, Pacifico A Cherchi G. Effect of pantethine on the subfractions of HDL in dyslipidemic patients. Curr Ther Res 1984;35:307-311.

Galeone F, Scalabrino A Giuntoli F Birindelli A Panigada G Rossi A et al. The lipid lowering effect of pantethine in hyperlipidemic patients: a clinical investigation. Curr Ther Res 1983;34:383-390.

Avogaro P, Bittolo G Fusello M. Effect of pantethine on lipids, lipoproteins and apolipoproteins in man. Curr Ther Res 1983;33:488-493.

Gleeson, J. M., Wittwer, C. T., Schipke, C. A., and Wilson, D. E. Effect of carnitine and pantethine on the metabolic abnormalities of acquired total lipodystrophy. Current Therapeutic Research 1987;41(Jan):83-88.

Pocecco, M. Treatment of infantile nephropathic cystinosis with cysteamine: 2. New England Journal of Medicine 1986;314(May 15):1320.

Braverman, E. R. Nutrition for the heart. Part 2. Natural Pharmacy 1999;3:22-24.

Pantethine. Monograph. Altern Med Rev. 2010;15(3):279-82.

Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. Vasc Health Risk Manag. 2014;10:89-100.

Chen YQ, Zhao SP, Zhao YH. Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study. J Clin Lipidol. 2015;9(5):692-7.

Chang X, Zhang J, Jiang Y, Yao B, Wang J, Wu Y. Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study. Orphanet J Rare Dis. 2020;15(1):248.

An Injectable for Advanced Cholesterol Care

What Really Works for High Cholesterol

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.

Pantethine - Uses, Side Effects, and More